Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APHENITY: Phase 3 Study of Sepiapterin in PKU
NCT05099640Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Sep 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 15
01
Overview
A Phase 3 trial of sepiapterin in phenylketonuria (PKU), sponsored by PTC Therapeutics, Inc.. Started Sep 2021; status: completed.
02
Drugs
sepiapterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05099640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099640.